Nitrendypina Egis (Nitrendipine)

Nitrendipine blocks L‑type calcium channels in vascular smooth‑muscle cells, preventing calcium entry that is necessary for contraction. This produces vasodilation of peripheral arteries, decreasing systemic vascular resistance and reducing blood pressure.

The appropriate dose is determined by the prescribing healthcare professional based on the individual’s clinical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with ACE inhibitors or beta‑blockers, nitrendipine belongs to the dihydropyridine calcium‑channel blocker class, offering potent arterial vasodilation with a lower incidence of negative inotropic effects. Choice of therapy depends on patient profile, comorbidities and physician preference.

Store the product at room temperature, below 25 °C, in the original packaging. Keep it away from excess moisture and direct sunlight to maintain stability and potency throughout its shelf life.

The medication is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

The most serious adverse events include severe hypotension, hepatic dysfunction, and hypersensitivity reactions such as rash or anaphylaxis. Patients should seek immediate medical attention if they experience symptoms like fainting, jaundice, or difficulty breathing.

Individuals with known hypersensitivity to nitrendipine or other dihydropyridine calcium‑channel blockers should avoid the drug. Caution is also advised in patients with severe hepatic impairment, unstable angina, or those taking contraindicated interacting medications.